Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunoge…
Closes 11 Feb 2027 (99 days)
up to USD 4,000,000. National Institutes of Health
Who can apply
- Where
- United States, nationwide
- Industries
- any, or not stated
- Business size
- not stated
- Amount
- up to USD 4,000,000
- Dates
- opens 13 Oct 2026; closes 11 Feb 2027
The funder's text has not been read for criteria yet; open the source for the full rules.
Eligibility, in the funder's words
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibilityForeign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
About the program
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.
Common questions
Am I eligible?
Only National Institutes of Health can say. The rules above are what the notice states; sign in and your business profile is compared with them line by line for a likely, maybe or unlikely verdict.
When does it close?
11 Feb 2027. Save it in your account for reminders 14, 7 and 2 days before.
Where do I apply?
On the funder's page: https://www.grants.gov/search-results-detail/361832
Is this one for you?
Sign in and your state, industry, size and turnover are compared with these rules line by line. Save it for closing reminders.